Light chain myeloma is a form of multiple myeloma in which cancerous plasma cells produce only the light chain portion of an antibody, without the accompanying heavy chain. It accounts for about 15 to 20% of all multiple myeloma cases. Because these incomplete antibody fragments are small enough to pass through the kidneys, light chain myeloma carries a notably higher risk of kidney damage than other forms of the disease and requires specific blood and urine tests to detect.
How Normal Antibodies Differ From Light Chains
Healthy plasma cells produce complete antibodies made of two heavy chains and two light chains locked together. In light chain myeloma, the malignant plasma cells lose the ability to manufacture heavy chains. Instead, they churn out excess free light chains, either the kappa or lambda type. These free light chains circulate in the blood, filter into the urine, and accumulate in organs where they can cause serious harm.
When free light chains show up in urine, they’re historically called Bence Jones proteins, named after the physician who first described them in the 1840s. The term is still used in lab reports. About 20% of all myeloma patients produce only these Bence Jones proteins with no detectable heavy chain component.
Why It’s Harder to Detect
Standard screening for myeloma often starts with serum protein electrophoresis, a blood test that separates proteins by size and charge to look for an abnormal spike. The problem is that free light chains are small molecules. They can slip below the detection threshold of standard electrophoresis, meaning the test may come back looking normal even when disease is present. This makes light chain myeloma a recognized diagnostic challenge.
The serum free light chain assay solved much of this problem. It directly measures the concentration of free kappa and lambda light chains in the blood and calculates a ratio between them. A skewed ratio signals that one type of light chain is being overproduced. The test is more sensitive than traditional electrophoresis for detecting light chain disease and has a shorter turnaround because light chains are cleared from the blood quickly, giving a near real-time snapshot of disease activity.
Urine testing still plays a role. A 24-hour urine collection with immunofixation electrophoresis can pick up Bence Jones proteins directly, though results can be affected by how well the kidneys are functioning. Current diagnostic guidelines generally recommend combining serum electrophoresis, serum free light chain testing, and urine studies together for the most accurate picture.
Kidney Damage Is the Major Concern
The defining complication of light chain myeloma is kidney injury. Free light chains are filtered by the kidneys, and when levels are high, they interact with a protein in the kidney’s filtration tubes called Tamm-Horsfall protein. This interaction creates solid casts that physically block the tubes, a condition called light chain cast nephropathy. The blockage can rupture the tube walls, triggering inflammation that compounds the damage.
Beyond simple obstruction, the excess light chains also generate harmful reactive molecules and activate inflammatory pathways inside kidney cells. Over time, this leads to scarring of kidney tissue (fibrosis) that can become permanent. Light chain cast nephropathy is now classified as a myeloma-defining event, meaning its presence alone is enough to confirm that treatment should begin, even without other symptoms. Acute kidney injury is one of the most common ways light chain myeloma first reveals itself.
Light chains can also deposit in other organs, including the heart, liver, and nerves. When these deposits form a specific type of misfolded protein structure, the condition is called AL amyloidosis, a serious complication that can affect organ function independently of the myeloma itself.
Symptoms and How It Presents
Many symptoms of light chain myeloma overlap with other forms of multiple myeloma: bone pain (especially in the back and ribs), fatigue, frequent infections, and unexplained weight loss. The difference is that kidney problems tend to appear earlier and more prominently. You might notice foamy urine, reduced urine output, swelling in the legs, or lab work showing elevated creatinine before bone lesions or other classic myeloma signs become obvious.
Because the abnormal protein doesn’t always show up on routine blood tests, some patients go through multiple rounds of evaluation before the diagnosis is made. If standard myeloma screening comes back negative but symptoms persist, a serum free light chain assay and urine immunofixation are the tests that typically reveal the problem.
How Light Chain Myeloma Is Treated
Treatment follows the same general framework as other types of multiple myeloma, with particular urgency around protecting kidney function. The core of modern therapy relies on three classes of drugs used in combination: proteasome inhibitors, which block a protein-recycling system that myeloma cells depend on to survive; immunomodulatory drugs, which stimulate the immune system to attack cancer cells while also directly harming them; and a steroid to amplify the effects of both.
Triplet regimens combining one drug from each class became the standard of care after clinical trials showed they improved both response depth and long-term survival compared to two-drug combinations. More recently, quadruplet regimens have become the new frontline standard. The FDA has approved a four-drug combination that adds a targeted antibody (which locks onto a protein called CD38 found on myeloma cells) to the existing triplet backbone. This approach is used for both patients who are candidates for stem cell transplant and those who are not, though the specific antibody approved differs between the two groups.
For patients whose kidneys are already compromised, rapid reduction of circulating light chains is critical. Treatment often begins immediately, sometimes before all diagnostic workups are complete, because the longer light chains remain elevated, the less likely kidney function is to recover.
Monitoring Treatment Response
One advantage of light chain myeloma, from a clinical monitoring perspective, is that free light chains have a short half-life in the blood. This means changes in disease activity show up in blood tests within hours to days, rather than the weeks it can take for intact immunoglobulins to reflect a treatment response. The serum free light chain assay becomes the primary tool for tracking whether therapy is working, with the kappa-to-lambda ratio serving as the key number doctors watch over time.
A normalizing ratio indicates that the overproduction of one light chain type is being brought under control. Persistently abnormal or worsening ratios signal that the current treatment may need to be changed. Urine monitoring can complement blood testing, particularly when kidney function is fluctuating, since the two measurements occasionally disagree and together provide a more complete picture.
Prognosis Compared to Other Myeloma Types
Light chain myeloma was historically considered to have a worse outlook than myeloma producing complete antibodies, largely because of the kidney damage and because it was harder to detect early. With modern drug combinations and better diagnostic tools, the gap has narrowed considerably. Outcomes depend heavily on the stage at diagnosis, the genetic features of the myeloma cells, and how much kidney function has been preserved.
Patients who achieve deep responses to initial treatment, where free light chains drop to undetectable levels, tend to have longer remissions regardless of which myeloma subtype they have. The shift to four-drug frontline regimens has improved response rates across all myeloma subtypes, including light chain disease, making early and aggressive treatment the most important factor in long-term outcomes.